A new study reveals that more than half of cancer drugs approved by the FDA under accelerated pathways are not authorized in ...
EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback